Suppr超能文献

NAD(P)H:醌氧化还原酶-1依赖性和非依赖性的强效醌Cdc25磷酸酶抑制剂的细胞毒性

NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.

作者信息

Han Yusheng, Shen Hongmei, Carr Brian I, Wipf Peter, Lazo John S, Pan Su-shu

机构信息

Department of Pharmacology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA 15213, USA.

出版信息

J Pharmacol Exp Ther. 2004 Apr;309(1):64-70. doi: 10.1124/jpet.103.059477. Epub 2004 Jan 12.

Abstract

Cdc25 dual-specificity phosphatases coordinate cell cycle progression and cellular signaling. Consequently, Cdc25 inhibitors represent potential anticancer agents. We evaluated >10,000 compounds for inhibition of human Cdc25 phosphatases and identified many potent and selective inhibitors, which all contained a quinone. Bioreductive enzymes frequently detoxify or activate quinones. Therefore, we evaluated the effect of NAD(P)H:quinone oxidoreductase-1 (NQO1) and reductase-rich microsomes on the activity of three quinone-containing Cdc25 inhibitors: 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone (Cpd 5, compound 5; NSC 672121), 2,3-bis-(2-hydroxyethylsulfanyl)-1,4-naphthoquinone (NSC 95397), and 6-chloro-7-(2-morpholin-4-yl-ethylamino)quinoline-5,8-dione (NSC 663284). Each inhibitor was reduced by human NQO1 (K(m) of 0.3-0.5 microM) but none by microsomes. Compounds were evaluated with six cancer cell lines containing different amounts of NQO1: HT-29 (1056 nmol/mg/min), HCT116 (660 nmol/mg/min), sublines HCT116-R30A (28 nmol/mg/min) and HCT-116R30A/NQ5 (934 nmol/mg/min), MDA-MB-231/Q2 (null NQO1), and subline MDA-MB-231/Q6 (124 nmol/mg/min) but containing similar amounts of microsomal cytochrome P450 reductase and cytochrome b(5) reductase. Growth inhibition and G2/M arrest by Cpd 5 was proportional to NQO1 levels, requiring 4- to 5-fold more Cpd 5 to inhibit HCT-116 or HCT-116R30A/NQ5 compared with HCT-116R30A. In contrast, in all tested cell lines irrespective of NQO1 level, growth inhibition and G2/M arrest by NSC 95375 and NSC 663284 were similar (average IC(50) of 1.3 +/- 0.3 and 2.6 +/- 0.4 microM, respectively). NSC 95375 and NSC 663284 also caused similar Cdk1 hyperphosphorylation, indicating similar Cdc25 inhibition. However, lower Cpd 5 concentrations were needed to produce Cdk1 hyperphosphorylation in sublines with minimal NQO1. Thus, NQO1 detoxified Cpd 5, probably by reducing it to a less active hydroquinone, whereas NSC 95397- and NSC 663284-generated cytotoxicity was unaffected by NQO1.

摘要

细胞分裂周期蛋白25(Cdc25)双特异性磷酸酶可协调细胞周期进程和细胞信号传导。因此,Cdc25抑制剂是潜在的抗癌药物。我们评估了10000多种化合物对人Cdc25磷酸酶的抑制作用,鉴定出许多强效且具选择性的抑制剂,这些抑制剂均含有醌类结构。生物还原酶常常使醌类解毒或激活醌类。因此,我们评估了烟酰胺腺嘌呤二核苷酸磷酸(NAD(P)H):醌氧化还原酶1(NQO1)和富含还原酶的微粒体对三种含醌类Cdc25抑制剂活性的影响,这三种抑制剂分别为:2-(2-羟乙基硫烷基)-3-甲基-1,4-萘醌(化合物5,Cpd 5;NSC 672121)、2,3-双(2-羟乙基硫烷基)-1,4-萘醌(NSC 95397)以及氯-7-(2-吗啉-4-基-乙氨基)喹啉-5,8-二酮(NSC 663284)。每种抑制剂均可被人NQO1还原(米氏常数为0.3 - 0.5微摩尔),但均不能被微粒体还原。我们用六种含有不同量NQO1的癌细胞系评估了这些化合物,这些癌细胞系分别为:HT-29(1056纳摩尔/毫克/分钟);HCT116(660纳摩尔/毫克/分钟);亚系HCT116-R30A(28纳摩尔/毫克/分钟)和HCT-116R30A/NQ5(934纳摩尔/毫克/分钟);MDA-MB-231/Q2(无NQO1);亚系MDA-MB-231/Q6(124纳摩尔/毫克/分钟),但这些细胞系中微粒体细胞色素P450还原酶和细胞色素b5还原酶的含量相似。Cpd 5对细胞生长的抑制作用和使细胞阻滞于G2/M期的作用与NQO1水平成正比,与HCT-亚系116R30A相比,抑制HCT-116或HCT-116R30A/NQ5所需的Cpd 5量要多4至5倍。相比之下,在所有测试的细胞系中,无论NQO1水平如何,NSC 95375和NSC 663284对细胞生长的抑制作用和使细胞阻滞于G2/M期的作用相似(平均半数抑制浓度分别为1.3±加/减0.3和2.6±加/减0.4微摩尔)。NSC 95375和NSC 663284还引起相似的细胞周期蛋白依赖性激酶1(Cdk1)过度磷酸化,表明它们对Cdc25的抑制作用相似。然而,在NQO1含量极低的亚系中,产生Cdk1过度磷酸化所需的Cpd 5浓度较低。因此,NQO1可能通过将Cpd 5还原为活性较低的对苯二酚而使其解毒,而NSC 95397和NSC 663284产生的细胞毒性不受NQO1的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验